Previous Close | 6.40 |
Open | 6.50 |
Bid | 5.60 |
Ask | 7.35 |
Strike | 45.00 |
Expire Date | 2024-01-19 |
Day's Range | 6.50 - 6.50 |
Contract Range | N/A |
Volume | |
Open Interest | 486 |
While Cassava Sciences, Inc. (NASDAQ:SAVA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 22%...
Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease.Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside of Neurodegeneration.Cash And Cash Equivalents Were $201 Million at Decemb